Lecanemab is a new drug used to treat early Alzheimer's disease(AD)with mild cog-nitive impairment or mild dementia.It is a human anti-Aβ fibril monoclonal IgG1 antibody,which is in-jected intravenously into the patient,through the blood-brain barrier into the brain,clearing amyloid plaque,thereby slowing the rate of cognitive de-cline in patients and delaying disease progression.This article reviews the pharmacological studies,clinical studies,safety and limitations of lecanem-ab,in order to help clinical understand the current research status and existing achievements of this drug.
维普
万方数据